ArticleVeterinary surgery : VS2025
Prognostic factors for short-term survival of cats that experienced postattenuation neurologic signs after surgical attenuation of single congenital portosystemic shunts.
Article in Veterinary surgery : VS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo report 30-day survival of cats that experienced postattenuation neurologic signs (PANS) after surgical attenuation of a single congenital portosystemic shunt (cPSS), and to investigate prognostic factors for short-term survival. STUDY
designMulti-institutional retrospective study. SAMPLE POPULATION: A total of 59 cats with cPSS that experienced PANS.
methodsThe medical records of 10 institutions were retrospectively reviewed to identify cats that underwent cPSS attenuation from January 1, 2010 through June 30, 2023 and developed PANS within 7 days postoperatively. Exclusion criteria were cats with arteriovenous malformation and cats lost-to-follow-up prior to 30 days. Logistic regression identified factors associated with 30-day survival. Odds Ratios (OR) and 95% CIs were calculated.
resultsA total of 46 (78.0%) PANS-affected cats survived to 30 days. A total of 13 (50.0%) of 26 cats that experienced postattenuation seizures (PAS) survived to 30 days, with most non-surviving cats experiencing generalized PAS. Cats that experienced PAS (p < .01, OR: 0.015, 95% CI: <0.001-0.281) and treatment of PANS with propofol (p < .01, OR: 0.112, 95% CI: 0.022-0.569) were associated with decreased odds of 30-day survival.
conclusionMost cats that experienced PANS survived to 30 days; however, short-term survival rate was worse for cats that experienced PAS. CLINICAL SIGNIFICANCE: The prognosis for cats that experience PANS is generally good but experiencing PAS and requiring treatment with propofol are negative prognostic factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.